Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc oxide + eugenol (commonly abbreviated as ZOE) is a combination dental material formed by mixing powdered zinc oxide with liquid eugenol (derived from clove oil). The mixture undergoes an acid-base reaction to form a chelate called zinc eugenolate. ZOE is widely used in dentistry as a temporary filling material, dental cement for crowns and bridges, root canal sealer, impression material for dentures, and periodontal dressing. It is valued for its sedative effect on the dental pulp due to the anti-inflammatory and local anesthetic properties of eugenol. Zinc oxide provides antimicrobial action and acts as an obtundant (pain-relieving agent). While it has low mechanical strength compared to permanent cements or restorative materials, it is biocompatible when applied on dentin but can be cytotoxic at high concentrations or if placed directly on pulp tissue. Modified versions with additives like EBA or polymers have improved mechanical properties but retain the basic mechanism of action[1][2][3][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc oxide + eugenol.